Investing in Biotechnology: Disrupting the Healthcare Space

06/17/21 | Roxanna Islam

Thematic Bio Banner

Investing in Biotechnology: Disrupting the Healthcare Space

Biotechnology companies are some of the largest disruptors within the broader healthcare sector—these companies create new and innovative treatments for critical diseases like cancer, Alzheimer’s disease, and more recently COVID-19. The S-Network Medical Breakthroughs Index (PMBI)—which is the underlying index for the ALPS Medical Breakthroughs ETF (SBIO)—and the S-Network Healthcare Innovation Index (PHIX)—which is the underlying index for the SmartTrust Healthcare Innovations Unit Investment Trust—both offer exposure to biotechnology stocks that have one or more drugs in Phase II and Phase III U.S. FDA trials. This strategy reduces the likelihood of early-stage failures in preclinical or Phase I trials, while still leaving potential for stock price growth once the drug is officially approved. See our detailed reports on PMBI here and PHIX here.

Another way biotech companies see significant stock price appreciation is through acquisitions. Since biotechnology companies focus on research & development, they are often acquired by large pharmaceutical companies which can market and distribute the treatment. In the most recent example, MorphoSys AG (MOR) recently announced the acquisition of biotechnology firm, Constellation Pharmaceuticals (CNST) at an approximately 70% premium to its previous closing price while CNST was a constituent of both PMBI and PHIX. According to DealForma, biopharma M&A activity grew (although total dollars decreased) from ~350 deals ($254 billion) in 2019 to 384 deals ($190.9 billion) in 2020. Deal activity so far in 2021 has been relatively muted, but strong innovation and competition could trigger a recovery in M&A activity.

One method to quantify biotechnology innovation is through the FDA’s novel drug approval list. The FDA defines novel drugs as “innovative products that serve previously unmet medical needs or otherwise significantly help to advance patient treatments” where the active ingredient has not previously been approved in the United States. In 2020, the FDA’s Center of Drug Evaluation and Research (CDER) approved 53 novel drugs—above the average rate of 40 novel drugs per year since 2011-2019. So far novel drug approvals in 2021 are about in line with last year with 26 drugs approved year-to-date as of June 7. Examples of novel drugs that have recently gained publicity are remdesivir (approved October 22, 2020 to treat COVID-19) and aducanumab (approved June, 7, 2021 to treat Alzheimer’s disease).

Given the volatility and uncertainty in the sector, biotechnology is a difficult space for individual stock picking and many investors instead choose to follow an index strategy. Broader healthcare indexes, however, tend to lack concentrated biotechnology exposure. The S&P 500 Health Care Index (S5HLTH) does not contain any PMBI or PHIX constituents, although it does contain larger biotechnology companies (all of its top 10 constituents have market caps over $100 billion). PMBI focuses on small to mid-cap stocks with market caps ranging from $200 million to $5 billion, while PHIX focuses on those with relatively higher market caps from $1 billion to $50 billion. The screening strategy behind PMBI and PHIX has helped achieve higher total return than S5HLTH over the past five years (115.6% for PMBI and 172.2% for PHIX compared to 91.0% for S5HLTH), which further validates its benefits over a broad-based sector strategy for those investors seeking a thematic growth opportunity.

06.17.2021 Graph


06.17.2021 Table-1

Related Research:

Biotechnology: Capturing Innovation and Potential M&A Upside
Capturing Biotech Innovators and M&A Targets
Investing in Space: Growth Beyond this World
Riding the ESG Wave by Investing in Water
How Is Digitization Impacting Businesses and Creating Opportunities for Investors?

Underlying Index | Associated Product/Direct-Indexing Platform Availability

S-Network Medical Breakthroughs Index (PMBI) | ALPS Medical Breakthroughs ETF (SBIO)
S-Network Healthcare Innovation Index (PHIX) | SmartTrust Healthcare Innovations Trust; Available on the C8 platform and the SMArtX platform

O'Shares Global Internet Giants Index (OGIGX) | O’Shares Global Internet Giants ETF (OGIG)
S-Network North American Disruptor Index (SNNADX) | SmartTrust Technology Revolution Trust – Includes 30 stocks from SNNADX
S-Network US Disruptor Index (SNUSDX) | Available on the SMArtX platform
S-Network Tech Target Index (SNTECH) | Available on the SMArtX Platform

S-Network Global Water Index (JGI) | Invesco Global Water Portfolio – Includes 25 stocks from JGI; Available on the C8 platform

Smart Climate Risk
S-Network Smart Climate Risk 50 Index (SNSC50) | Available on the C8 platform and the SMArtX platform S-Network Smart Climate Risk 250 Index (SNSC250) | Available on the C8 platform

S-Network Infrastructure Builders Index (EIBI) | Available on the C8 platform
S-Network Space Index (SPACE) | Procure Space ETF (UFO)
S-Network MicroSectors Gold Miners Index (MINERS) | MicroSectors Gold Miners 3x Leveraged ETN (GDXU), MicroSectors Gold Miners -3x Inverse Leveraged ETN (GDXD)

Download PDF